Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript
Aug. 3, 2018 12:32 AM ET | About: Arbutus Biopharma Corp (ABUS)
Q2: 07-26-18 Earnings Summary
Press Release News
EPS of $-0.44 Revenue of $1.2M (+ 20.0% Y/Y)
Arbutus Biopharma Corp (NASDAQ:ABUS) Q2 2018 Earnings Conference Call August 2, 2018 4:30 PM ET
Executives
Pam Murphy - IR
Mark Murray - CEO
Michael Sofia - CSO
William Symonds - Chief Development Officer
David Hastings - CFO
Koert VandenEnden - Chief Accounting Officer
Analysts
Liisa Bayko - JMP Securities
Katherine Xu - William Blair
Keay Nakae - Chardan
Madhu Kumar - B. Riley FBR
Operator
Good afternoon, ladies and gentlemen, and welcome to the Arbutus Biopharma Second Quarter 2018 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder this conference call is being recorded.
I'll now turn the call over to Pam Murphy, who has recently joined the Arbutus team as their IR Consultant. You may begin.
Pam Murphy
Thank you, operator. And good afternoon everyone and thanks for joining us. With me today are Dr. Mark Murray, Arbutus' CEO; Dr. Mike Sofia, Arbutus' Chief Scientific Officer; Dr. Bill Symonds, Arbutus' Chief Development Officer; Dave. Hastings, Arbutus' Chief Financial Officer; and, Koert VandenEnden, Arbutus' Chief Accounting Officer.
Before we begin, let me remind you that some of the statements made during the call today, are forward-looking statements including statements regarding developing accure for chronic HBV, the clinical development plan and potential for AB-506 and AB-452, Genevant development of delivery technologies and the potential of a development partnership, our clinical plan for ARB-1467 along with potential efficacy and timing of reported results, our expected cash runway, timing of regulatory filings and approval and expected revenues from our current and potential licensing agreements.
All of these statements involve certain assumptions, risks and uncertainties that are beyond our control and can cause our actual results to differ materially. A description of these risks can be found in our latest disclosure documents and current press releases. In addition, Arbutus does not undertake any obligation to update any forward-looking statements made during this call.
I'd now like to pass the call to Mark for his introductory remarks.
Mark Murray
Thanks, Pam. And thank you to everyone for joining us on the call today. Our mission is to develop a cure for chronic hepatitis B using a combination of orally active therapeutic agents, which is effective in the defined treatment duration. To that end, we have developed a pipeline of proprietary therapeutic agents that target multiple agents of the HPV lifecycle, the most important of which are HPV data replication and HPV surface antigen expression.
Last month, we initiated our Phase 1A/1B clinical trial of AB-506 our second generation capsid inhibitor agent. We will shortly file our regulatory submission to start the Phase 1A/1B clinical study of our RNA destabilizer agent AB-452. We expect patient monotherapy results from both of these studies by mid-2019 and we expect to combine these in the first ever oral combination study by the end of 2019.
In addition during the first half of the year we completed a number of strategic initiatives to keep our team, our business activities and our capital resources more closely focused on HPV. We have successfully completed a site consolidation that concentrates our business activities in a single location in Warminster, Pennsylvania. We have successfully launched Genevant Sciences together with Roivant.
Genevant is wholly focused on utilizing Arbutus's proprietary LNP and ligand conjugate delivery technologies to develop RNA-based therapies and we've retained a substantial equity interest in Genevant as well as the potential for future royalties on commercialized products. We're encouraged by Genevant's recently announced partnership with BioNTech for the co-development of five mRNA products which we see as being potentially a transformative partnership in the field combining an industry leading mRNA portfolio with the industry leading delivery technologies of Genevant.作者: newchinabok 时间: 2018-8-3 15:34